Search results

146 results

Sorted by Relevance . Sort by Date

Guidance Remove Guidance filter
Proposed Remove Proposed filter
In consultation Remove In consultation filter
Technology appraisal guidance Remove Technology appraisal guidance filter
COVID-19 rapid guidelines Remove COVID-19 rapid guidelines filter
Diagnostics guidance Remove Diagnostics guidance filter

Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma after 1 systemic treatment [ID3869]

Proposed [GID-TA10757] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Treprostinil for treating symptomatic chronic thromboembolic pulmonary hypertension [ID3926 ]

Proposed [GID-TA10821] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Burosumab for treating FGF23-related hypophosphataemia in tumour-induced osteomalacia [ID3924 ]

Proposed [GID-TA10822] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Inolimomab (Leukotac) for acute Graft versus host disease (aGvHD) after Allo-HSCT [ID3923]

Proposed [GID-TA10823] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy [ID3928]

Proposed [GID-TA10824] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Avatrombopag in combination for treating chronic immune thrombocytopenia [ID3838]

Proposed [GID-TA10738] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Avatrombopag for treating chemotherapy-induced thrombocytopenia in non-haematological cancers [ID3837]

Proposed [GID-TA10737] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Ozanimod for treating moderately to severely active ulcerative colitis [ID3841]

Proposed [GID-TA10732] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID3860]

Proposed [GID-TA10746] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Evinacumab for treating homozygous familial hypercholesterolaemia in people aged 12 and over [ID2704]

Proposed [GID-TA10655] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Liposomal bupivacaine for treating postoperative pain [ID3799]

Proposed [GID-TA10681] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Remimazolam for sedation for people having diagnostic or therapeutic procedures [ID3758]

Proposed [GID-TA10720] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Fostemsavir for treating adults with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2726]

Proposed [GID-TA10605] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer [ID3920 ]

Proposed [GID-TA10802] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Amcenestrant for treating ER-positive, HER2-negative advanced breast cancer after hormonal therapy [ID3919]

Proposed [GID-TA10803] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed

Filter (6 in use)

Type 1 selected

Status 2 selected

Last updated

Guidance programme 3 selected

146 results

Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma after 1 systemic treatment [ID3869]

Treprostinil for treating symptomatic chronic thromboembolic pulmonary hypertension [ID3926 ]

Burosumab for treating FGF23-related hypophosphataemia in tumour-induced osteomalacia [ID3924 ]

Inolimomab (Leukotac) for acute Graft versus host disease (aGvHD) after Allo-HSCT [ID3923]

Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy [ID3928]

Avatrombopag in combination for treating chronic immune thrombocytopenia [ID3838]

Avatrombopag for treating chemotherapy-induced thrombocytopenia in non-haematological cancers [ID3837]

Ozanimod for treating moderately to severely active ulcerative colitis [ID3841]

Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID3860]

Evinacumab for treating homozygous familial hypercholesterolaemia in people aged 12 and over [ID2704]

Liposomal bupivacaine for treating postoperative pain [ID3799]

Remimazolam for sedation for people having diagnostic or therapeutic procedures [ID3758]

Fostemsavir for treating adults with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2726]

Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer [ID3920 ]

Amcenestrant for treating ER-positive, HER2-negative advanced breast cancer after hormonal therapy [ID3919]